Trial Profile

Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
Indications Paraproteinaemia; Peripheral neuropathies; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use

Most Recent Events

12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
13 Apr 2022 Trial design presented at the 113th Annual Meeting of the American Association for Cancer Research
22 Nov 2021 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com